3 results
Approved WMOCompleted
Can administration of scopolaminebutyl from the start of the dying phase prevent death rattle during the dying phase?
Approved WMORecruiting
This Phase Ia/Ib study will evaluate the safety, pharmacokinetics, immunogenicity (as applicable for study biotherapeutics), preliminary activity, and biomarkers of GDC-6036 as a single agent (Arm A) and in combination with other anti-cancer…
Approved WMORecruiting
Dose escalationPrimary• To determine the RP2D of single-agent petosemtamab in mCRC patients who have progressed on chemotherapy, with or without an anti-VEGF therapy, and with an anti-EGFR therapy (if RASwt)Secondary• To characterize the safety and…